Trump orders 100% tariffs on patented drug imports, restructures metal duties, sparking market jitters

Tariffs are taxes imposed on imported goods and can be used as a protectionist measure to shield domestic industries from foreign competition or as a tool in trade negotiations. U.S. trade policy under previous Trump administrations often favored tariffs to address perceived trade imbalances and enforce intellectual property rights. The pharmaceutical industry, with its complex global supply chains and patent regimes, is particularly sensitive to such policy shifts. This latest order specifically targets patented drugs, potentially forcing pharmaceutical companies to lower prices in the U.S. market or shift manufacturing. While the U.S. is a major market for India's generic drug exports, the direct impact of these new tariffs on India is expected to be minimal as Indian pharmaceutical exports primarily consist of generics, which are currently exempt. However, any broader trade war or retaliatory measures could have wider consequences. This development is significant for understanding international trade, economic policy, and global supply chains. For competitive exams, it highlights the use of protectionist measures, the dynamics of the global pharmaceutical industry, and the specific impact of U.S. trade policies on emerging economies like India. It also touches upon issues of intellectual property rights and access to affordable medicines.